BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to MDA-MB-231 cell line is 938
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by Western Blotting and IF staining | NA | 0.64 | 1 | 29207686 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | RH-1 | qRT-PCR followed by FACs and Western Blotting | NA | 0.64 | 1 | 31336714 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and IF staining | NA | 0.64 | 1 | 29100426 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA followed by Western Blotting | NA | 0.64 | 1 | 34451892 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by Western Blotting and SFA | NA | 0.64 | 1 | 29316250 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and IF staining | NA | 0.64 | 1 | 33274565 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and IF staining | NA | 0.64 | 1 | 34311079 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and IF staining | NA | 0.64 | 1 | 35413424 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and IF staining | NA | 0.64 | 1 | 31612865 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs and qRT-PCR | NA | 0.64 | 1 | 34146553 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs and qRT-PCR | NA | 0.64 | 1 | 34445421 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs and qRT-PCR | NA | 0.64 | 1 | 35195687 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by qPCR and SFA | NA | 0.64 | 1 | 31745977 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by qRT-PCR and SFA | NA | 0.64 | 1 | 30239174 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Gemcitabine | CFA and SFA followed by Western Blotting | NA | 0.64 | 1 | 28036386 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.64 | 1 | 30262865 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.64 | 1 | 31497349 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs and FACs | NA | 0.64 | 1 | 34235281 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | IF staining | NA | 0.64 | 1 | 28760736 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SP assay followed by SFA and IHC staining | NA | 0.64 | 1 | 29981340 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Lapatinib | SFA followed by qRT-PCR | NA | 0.64 | 1 | 34435487 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.64 | 1 | 30513573 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and qRT-PCR | NA | 0.64 | 1 | 31728117 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.64 | 1 | 29103027 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.64 | 1 | 29179185 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 33433838 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 33731668 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 34073849 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 34665934 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 35055160 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 35084278 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by CFA | NA | 0.64 | 1 | 34502547 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 32482103 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | FACs followed by SFA | NA | 0.64 | 1 | 33221681 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Carboplatin | FACs followed by SFA | NA | 0.64 | 1 | 33221681 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | FACs followed by SFA | NA | 0.64 | 1 | 33221681 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 34294320 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 34770867 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 34944852 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 35135840 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 35171381 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 35205696 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 35504883 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA followed by | NA | 0.64 | 1 | 34344863 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs followed by SFA | NA | 0.64 | 1 | 33845139 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and FACs | NA | 0.64 | 1 | 33390847 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and FACs | NA | 0.64 | 1 | 34234874 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 33419140 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 33511560 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 33866606 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 34052833 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 34123797 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 34130123 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 34249423 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 34608584 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 35017469 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 35277657 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 35526049 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | CFA followed by FACs | NA | 0.64 | 1 | 28839461 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 18366788 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29036915 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29162703 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29262622 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29290211 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29323439 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29374148 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29394261 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29526821 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29552056 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29552056 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29653746 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 29848346 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 30191610 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 30191610 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 30233203 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 30246563 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Radiotherapy | FACs | NA | 0.64 | 1 | 30272295 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 30584335 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.64 | 1 | 31729259 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | FACs and SFA | NA | 0.64 | 1 | 28703802 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Docetaxel | FACs and SFA | NA | 0.64 | 1 | 29921732 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by CFA | NA | 0.64 | 1 | 18681906 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cisplatin | FACs followed by CFA | NA | 0.64 | 1 | 30255421 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 27976692 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 28817737 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 29048610 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Docetaxel | FACs followed by SFA | NA | 0.64 | 1 | 29190901 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 29197410 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 29218545 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 29249663 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 29353288 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 29601799 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Epirubicin | FACs followed by SFA | NA | 0.64 | 1 | 29792857 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 29797562 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 30021199 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 30450530 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 30460610 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 30479839 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 30542507 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 30587555 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31283068 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31501409 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31545416 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31545416 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31599500 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31619923 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31695436 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31695775 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.64 | 1 | 31695775 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and Migration assay | NA | 0.64 | 1 | 31756533 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cisplatin | FACs followed by SP assay and SFA | NA | 0.64 | 1 | 30361903 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by Tumorigenicity assay | NA | 0.64 | 1 | 29658391 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by Tumorigenicity assay | NA | 0.64 | 1 | 30050079 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs followed by SFA | NA | 0.64 | 1 | 29301945 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and CFA followed by MACs | NA | 0.64 | 1 | 29187905 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA followed by FACs | NA | 0.64 | 1 | 28817737 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 28817737 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 28823831 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by FACs | NA | 0.64 | 1 | 28835684 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 28923385 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 28928832 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 28951456 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 28991374 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 29053396 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 29228728 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 29405062 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Fructose | SFA followed by FACs | NA | 0.64 | 1 | 29796188 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 29895705 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 29964299 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 29975921 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 30002443 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 30149665 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 30170097 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 30564555 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | 7 Gy Radiation | SFA followed by FACs | NA | 0.64 | 1 | 30579251 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 30647871 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 31273952 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 31308814 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 31452727 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 31462709 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 31658701 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 31726667 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.64 | 1 | 31784862 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | ALDEFLUOR assay and SFA followed by Western Blotting and qPCR | NA | 0.6 | 0.684 | 28703802 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | CFA followed by IF staining and Western Blotting | NA | 0.6 | 0.684 | 28839461 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.6 | 0.684 | 33866606 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.6 | 0.684 | 34249423 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA and qRT-PCR | NA | 0.6 | 0.684 | 34528694 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.6 | 0.684 | 29848346 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and Western Blotting | NA | 0.6 | 0.684 | 30541574 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR followed by Western Blotting | NA | 0.6 | 0.684 | 28760736 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay and Western Blotting | NA | 0.6 | 0.684 | 35004266 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting and FACs | NA | 0.6 | 0.684 | 33924995 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 33797754 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | ALDEFLUOR assay and Western Blotting followed by SFA | NA | 0.6 | 0.684 | 29880481 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by Western Blotting and SFA | NA | 0.6 | 0.684 | 29316250 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Radiotherapy | FACs followed by Western Blotting | NA | 0.6 | 0.684 | 30272295 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs followed by Western Blotting | NA | 0.6 | 0.684 | 29228728 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay and Western Blotting | NA | 0.6 | 0.684 | 31497349 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR and SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 31745977 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and ALDEFLUOR assay and SFA | NA | 0.6 | 0.684 | 30513573 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay and RT-PCR | NA | 0.6 | 0.684 | 30131941 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.6 | 0.684 | 29353288 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.684 | 31695775 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.6 | 0.684 | 29869379 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.6 | 0.684 | 31283068 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay and FACs | NA | 0.6 | 0.684 | 31658701 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.6 | 0.684 | 33634797 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.6 | 0.684 | 33845139 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cyclophosphamide | qRT-PCR | NA | 0.6 | 0.684 | 33090711 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.684 | 33090711 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Lapatinib | SFA followed by qRT-PCR | NA | 0.6 | 0.684 | 34435487 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.684 | 35017469 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.6 | 0.684 | 30239174 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR followed by SFA | NA | 0.6 | 0.684 | 31850822 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and qRT-PCR | NA | 0.6 | 0.684 | 31728117 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.684 | 29179185 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | 8 Gy Radiation | SFA followed by RT-PCR | NA | 0.6 | 0.684 | 30579251 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay and SFA | NA | 0.6 | 0.684 | 34298877 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 33221681 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Carboplatin | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 33221681 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 33221681 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 34311079 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 34344863 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 34451892 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 34770867 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 34944852 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 35135840 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 35171381 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 35216080 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 35216080 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 35504883 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Irradiation | CFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 34708581 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.6 | 0.684 | 34073849 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and ALDEFLUOR assay | NA | 0.6 | 0.684 | 34234874 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA and ALDEFLUOR assay | NA | 0.6 | 0.684 | 35401817 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 33057995 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 33510281 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 33525605 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 33672732 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 34123797 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 34146553 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 34178639 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 34420298 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 34445421 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 34990518 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 35195687 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 35277657 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDREFLUOR assay | NA | 0.6 | 0.684 | 33419140 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay | NA | 0.6 | 0.684 | 29207686 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay | NA | 0.6 | 0.684 | 29290211 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay | NA | 0.6 | 0.684 | 29374148 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay | NA | 0.6 | 0.684 | 29500278 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay | NA | 0.6 | 0.684 | 30301222 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay | NA | 0.6 | 0.684 | 30322103 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay | NA | 0.6 | 0.684 | 30478301 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay and SFA | NA | 0.6 | 0.684 | 27976692 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay and SFA | NA | 0.6 | 0.684 | 29197410 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Docetaxel | ALDEFLUOR assay and SFA | NA | 0.6 | 0.684 | 29921732 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by CFA | NA | 0.6 | 0.684 | 18681906 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Bevacizumab | ALDEFLUOR assay followed by Migration and Invasion assay | NA | 0.6 | 0.684 | 31497360 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 28817737 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 29027990 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 29601799 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 29907642 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 30052635 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 30460610 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 30542507 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 30587555 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 31534364 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA | NA | 0.6 | 0.684 | 31619923 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | ALDEFLUOR assay followed by SFA and SP assay | NA | 0.6 | 0.684 | 27974826 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.6 | 0.684 | 29162703 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.6 | 0.684 | 31666201 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.6 | 0.684 | 31545416 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and CFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 29187905 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 28817737 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 28823831 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 28835684 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 29073729 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 29106390 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 29137219 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 29383157 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Fructose | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 29796188 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 30032164 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 30149665 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 30639386 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 30647871 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 30971005 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by ALDEFLUOR assay | NA | 0.6 | 0.684 | 31529195 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.6 | 0.684 | 31726667 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and IF staining | NA | 0.52 | 0.456 | 29100426 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by IF staining | NA | 0.52 | 0.456 | 29207686 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by qRT-PCR and SFA | NA | 0.52 | 0.456 | 30239174 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | IF staining | NA | 0.52 | 0.456 | 28760736 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SP assay followed by SFA and IHC staining | NA | 0.52 | 0.456 | 29981340 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.52 | 0.456 | 29103027 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | CFA followed by FACs | NA | 0.52 | 0.456 | 28839461 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 18366788 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29036915 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29162703 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29262622 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29290211 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29323439 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29374148 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29526821 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29552056 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29552056 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29653746 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 29848346 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 30191610 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 30191610 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 30233203 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 30246563 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Radiotherapy | FACs | NA | 0.52 | 0.456 | 30272295 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 30584335 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.52 | 0.456 | 31729259 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | FACs and SFA | NA | 0.52 | 0.456 | 28703802 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Docetaxel | FACs and SFA | NA | 0.52 | 0.456 | 29921732 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by CFA | NA | 0.52 | 0.456 | 18681906 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cisplatin | FACs followed by CFA | NA | 0.52 | 0.456 | 30255421 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 27976692 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 28817737 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Docetaxel | FACs followed by SFA | NA | 0.52 | 0.456 | 29190901 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 29197410 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 29218545 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 29249663 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 29316250 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 29353288 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 29601799 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Epirubicin | FACs followed by SFA | NA | 0.52 | 0.456 | 29792857 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 29797562 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 30021199 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 30450530 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 30460610 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 30479839 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 30542507 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 30587555 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31283068 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31501409 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31545416 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31599500 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31612865 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31619923 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31695436 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31695775 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.52 | 0.456 | 31695775 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and Migration assay | NA | 0.52 | 0.456 | 31756533 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cisplatin | FACs followed by SP assay and SFA | NA | 0.52 | 0.456 | 30361903 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by Tumorigenicity assay | NA | 0.52 | 0.456 | 29658391 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by Tumorigenicity assay | NA | 0.52 | 0.456 | 30050079 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs followed by SFA | NA | 0.52 | 0.456 | 29301945 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and CFA followed by MACs | NA | 0.52 | 0.456 | 29187905 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 28817737 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 28823831 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by FACs | NA | 0.52 | 0.456 | 28835684 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 28923385 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 28928832 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 28951456 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 28991374 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 29053396 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 29228728 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 29405062 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Fructose | SFA followed by FACs | NA | 0.52 | 0.456 | 29796188 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 29895705 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 29964299 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 29975921 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 30002443 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 30149665 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 30170097 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 30564555 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | 6 Gy Radiation | SFA followed by FACs | NA | 0.52 | 0.456 | 30579251 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 30647871 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 31273952 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 31308814 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 31452727 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 31462709 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 31658701 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 31726667 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.52 | 0.456 | 31784862 |
| GPT2 | 18062 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | CFA followed by IF staining and Western Blotting | NA | 0.52 | 0.0011 | 28839461 |
| NANOG | 20857 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA followed by single-cell time-of-flight mass cytometry | Up | 0.48 | 0.5461 | 34831064 |
| PROM1 | 9454 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA and FACs followed by single-cell time-of-flight mass cytometry | Up | 0.48 | 0.7582 | 34831064 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 34249423 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR followed by Western Blotting | NA | 0.48 | 0.1739 | 28760736 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 34789263 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.1739 | 34770867 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 31756533 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR followed by SFA | NA | 0.48 | 0.1739 | 29907642 |
| ABCG2 | 74 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1739 | 29103027 |
| ADORA2B | 264 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and qRT-PCR followed by SFA | NA | 0.48 | 0.0042 | 29218545 |
| ADORA2B | 264 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0042 | 35401817 |
| BAG3 | 939 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 28703799 |
| BIRC5 | 593 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and RT-PCR followed by SFA | NA | 0.48 | 0.0053 | 29383157 |
| BIRC5 | 593 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.48 | 0.0053 | 29197410 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting and RT-PCR | NA | 0.48 | 0.1135 | 28914785 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 34789263 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.1135 | 34294320 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 31308814 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting | NA | 0.48 | 0.1135 | 29394261 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1135 | 35195687 |
| CD47 | 1682 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 31273952 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and RT-PCR followed by SFA | NA | 0.48 | 0.0647 | 29383157 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.48 | 0.0647 | 34502547 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0647 | 34451892 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting | NA | 0.48 | 0.0647 | 29100426 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.0647 | 27976692 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by IF staining | NA | 0.48 | 0.0647 | 33511560 |
| CXCR3 | 4540 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qPCR and Western Blotting | NA | 0.48 | 0.0011 | 31619923 |
| CXCR4 | 2561 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0498 | 34070538 |
| CXCR4 | 2561 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0498 | 28703799 |
| CXCR4 | 2561 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.48 | 0.0498 | 29353288 |
| CXCR4 | 2561 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.48 | 0.0498 | 35413424 |
| CXCR4 | 2561 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs and SFA | NA | 0.48 | 0.0498 | 31745977 |
| CXCR4 | 2561 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.48 | 0.0498 | 31545416 |
| DROSHA | 17904 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0011 | 32859993 |
| FSTL1 | 3972 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 30336071 |
| GJB2 | 4284 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR and Western Blotting followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0032 | 29422613 |
| GSK3B | 4617 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and RT-PCR followed by SFA | NA | 0.48 | 0.0053 | 29383157 |
| HSPA9 | 5244 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 34249423 |
| KDM1A | 29079 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 33057995 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0891 | 35401817 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and IHC staining | NA | 0.48 | 0.0891 | 30131941 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0891 | 34451892 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0891 | 29137219 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0891 | 30262865 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.0891 | 29287960 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.0891 | 29316250 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | Western Blotting followed by SFA | NA | 0.48 | 0.0891 | 29880481 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cyclophosphamide | qRT-PCR | NA | 0.48 | 0.0891 | 33090711 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.0891 | 33090711 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 32859993 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.1304 | 30149665 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and RT-PCR followed by SFA | NA | 0.48 | 0.1304 | 28951456 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and IHC staining | NA | 0.48 | 0.1304 | 30131941 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 34789263 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.1304 | 35504883 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 28914785 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 29106390 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 30262865 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1304 | 30647871 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.1304 | 29287960 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR followed by SFA | NA | 0.48 | 0.1304 | 35135840 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.48 | 0.1304 | 34298877 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.48 | 0.1304 | 35413424 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1304 | 34146553 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1304 | 34445421 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.1304 | 35326667 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.1304 | 30450530 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.1304 | 31658701 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.48 | 0.1304 | 29197410 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.48 | 0.1304 | 29383157 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qPCR | NA | 0.48 | 0.1304 | 28703802 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA followed by FACs | NA | 0.48 | 0.1304 | 28817737 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cyclophosphamide | qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 33090711 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 35055160 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 32859993 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 33090711 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 33866606 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 34070538 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 34249423 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 35401817 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 29848346 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 28703799 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 29601799 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 30336071 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and IHC staining | NA | 0.48 | 0.5461 | 30131941 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Irradiation | CFA followed by Western Blotting | NA | 0.48 | 0.5461 | 34708581 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 33390847 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 33530373 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by SP assay and Western Blotting | NA | 0.48 | 0.5461 | 35004266 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 34178639 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 34770867 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | CFA followed by Western Blotting | NA | 0.48 | 0.5461 | 28839461 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and SP assay followed by Western Blotting | NA | 0.48 | 0.5461 | 28903350 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 28823831 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29137219 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29422613 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29797562 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29981340 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 30262865 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 31695775 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.5461 | 30482236 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.5461 | 31501409 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 29880481 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 31584203 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culture of cells in electrospun scaffolds followed by qRT-PCR | NA | 0.48 | 0.5461 | 34841239 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by RT-PCR | NA | 0.48 | 0.5461 | 34235281 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.48 | 0.5461 | 34298877 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 33511560 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34052833 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34146553 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34420298 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34445421 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 34990518 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 35017469 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 35195687 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 35326667 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR and SFA | NA | 0.48 | 0.5461 | 31745977 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 30021199 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 30542507 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.5461 | 30052635 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.5461 | 31658701 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.48 | 0.5461 | 29197410 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5461 | 28991374 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and RT-PCR | NA | 0.48 | 0.5461 | 29964299 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qPCR | NA | 0.48 | 0.5461 | 28703802 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 28871147 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 28871147 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 30587555 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | 9 Gy Radiation | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 30579251 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SP assay followed by qPCR | NA | 0.48 | 0.5461 | 30110679 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA followed by FACs | NA | 0.48 | 0.5461 | 28817737 |
| NRP1 | 8004 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0053 | 29179185 |
| NRP1 | 8004 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs and SFA | NA | 0.48 | 0.0053 | 31745977 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cyclophosphamide | qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 33090711 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 32859993 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 33090711 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 34070538 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 34249423 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 35029026 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 35401817 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 29848346 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 29601799 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and RT-PCR | NA | 0.48 | 0.6448 | 29511337 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs followed by Western Blotting | NA | 0.48 | 0.6448 | 29228728 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Irradiation | CFA followed by Western Blotting | NA | 0.48 | 0.6448 | 34708581 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.48 | 0.6448 | 33731668 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 33390847 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 33530373 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 34178639 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.6448 | 35504883 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 34528694 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 34770867 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Gemcitabine | CFA and SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 28036386 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | CFA followed by Western Blotting | NA | 0.48 | 0.6448 | 28839461 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and SP assay followed by Western Blotting | NA | 0.48 | 0.6448 | 28903350 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 28823831 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 29106390 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 29137219 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 29422613 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 29797562 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 29981340 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 30647871 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 31695775 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting | NA | 0.48 | 0.6448 | 29100426 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Radiotherapy | Western Blotting | NA | 0.48 | 0.6448 | 30272295 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.6448 | 30482236 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.6448 | 31501409 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 29218545 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 29880481 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.48 | 0.6448 | 31584203 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.48 | 0.6448 | 33634797 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by RT-PCR | NA | 0.48 | 0.6448 | 34235281 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR followed by SFA | NA | 0.48 | 0.6448 | 35135840 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.48 | 0.6448 | 34298877 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 33511560 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 34052833 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 34146553 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 34420298 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 34445421 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 34990518 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 35195687 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 35326667 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR and SFA | NA | 0.48 | 0.6448 | 31745977 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.48 | 0.6448 | 30021199 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.48 | 0.6448 | 30542507 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.48 | 0.6448 | 30239174 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.6448 | 30052635 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.6448 | 30450530 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.6448 | 31658701 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.48 | 0.6448 | 29197410 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and qRT-PCR | NA | 0.48 | 0.6448 | 28991374 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and qRT-PCR | NA | 0.48 | 0.6448 | 31728117 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and RT-PCR | NA | 0.48 | 0.6448 | 29964299 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qPCR | NA | 0.48 | 0.6448 | 28703802 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 28871147 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 28871147 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 30587555 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.6448 | 30149665 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | 10 Gy Radiation | SFA followed by RT-PCR | NA | 0.48 | 0.6448 | 30579251 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SP assay followed by qPCR | NA | 0.48 | 0.6448 | 30110679 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 34070538 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.7582 | 30336071 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting and FACs | NA | 0.48 | 0.7582 | 33924995 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA followed by FACs | NA | 0.48 | 0.7582 | 33797754 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.7582 | 34294320 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.7582 | 29869379 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | IF staining and SFA | NA | 0.48 | 0.7582 | 35413424 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cyclophosphamide | qRT-PCR | NA | 0.48 | 0.7582 | 33090711 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.7582 | 33090711 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Lapatinib | SFA followed by qRT-PCR | NA | 0.48 | 0.7582 | 34435487 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.48 | 0.7582 | 30021199 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SP assay followed by qPCR | NA | 0.48 | 0.7582 | 30110679 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.48 | 0.7582 | 35055160 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SP assay followed by FACs | NA | 0.48 | 0.7582 | 29907642 |
| RAB27A | 9766 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 28928832 |
| SCUBE2 | 30425 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 29981340 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 35055160 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 33866606 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 35401817 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 29848346 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 28703799 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 29601799 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 30336071 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR and IHC staining | NA | 0.48 | 0.5695 | 30131941 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by qRT-PCR | NA | 0.48 | 0.5695 | 30255421 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Irradiation | CFA followed by Western Blotting | NA | 0.48 | 0.5695 | 34708581 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.48 | 0.5695 | 33731668 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.48 | 0.5695 | 33390847 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 34178639 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 34789263 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 34528694 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | CFA followed by Western Blotting | NA | 0.48 | 0.5695 | 28839461 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and SP assay followed by Western Blotting | NA | 0.48 | 0.5695 | 28903350 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 28823831 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 29137219 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 29383157 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 29422613 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 29797562 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 29981340 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 31308814 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 31695775 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting | NA | 0.48 | 0.5695 | 29100426 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.5695 | 29956731 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.5695 | 30482236 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.48 | 0.5695 | 31501409 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 29218545 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 29880481 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 31584203 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culture of cells in electrospun scaffolds followed by qRT-PCR | NA | 0.48 | 0.5695 | 34841239 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.48 | 0.5695 | 33634797 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR followed by SFA | NA | 0.48 | 0.5695 | 35135840 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cyclophosphamide | qRT-PCR | NA | 0.48 | 0.5695 | 33090711 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.48 | 0.5695 | 34298877 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 33090711 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 33511560 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 34420298 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Lapatinib | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 34435487 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 34445421 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 34990518 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 35017469 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 35029026 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 35195687 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 35326667 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR and SFA | NA | 0.48 | 0.5695 | 31745977 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.48 | 0.5695 | 30021199 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.48 | 0.5695 | 30542507 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.48 | 0.5695 | 30239174 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.5695 | 30052635 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.48 | 0.5695 | 31658701 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5695 | 28991374 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and RT-PCR | NA | 0.48 | 0.5695 | 29964299 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qPCR | NA | 0.48 | 0.5695 | 28703802 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cisplatin | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 28871147 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 28871147 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 30587555 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5695 | 30149665 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | 11 Gy Radiation | SFA followed by RT-PCR | NA | 0.48 | 0.5695 | 30579251 |
| TENM4 | 29945 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 33672732 |
| UBQLN1 | 12508 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by qRT-PCR and Western Blotting and SFA | NA | 0.48 | 0.0021 | 34528694 |
| VEGFA | 12680 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 29179185 |
| DCLK1 | 2700 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting and FACs | NA | 0.4 | 0.0159 | 33924995 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and IF staining | NA | 0.36 | 0.456 | 33274565 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and IF staining | NA | 0.36 | 0.456 | 34311079 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.36 | 0.456 | 31497349 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs and FACs | NA | 0.36 | 0.456 | 34235281 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Lapatinib | SFA followed by qRT-PCR | NA | 0.36 | 0.456 | 34435487 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.36 | 0.456 | 33433838 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.36 | 0.456 | 33731668 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.36 | 0.456 | 34665934 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.36 | 0.456 | 35055160 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.36 | 0.456 | 35084278 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by CFA | NA | 0.36 | 0.456 | 34502547 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 32482103 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 34294320 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 34344863 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 34451892 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 34944852 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 35135840 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 35205696 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 35413424 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.36 | 0.456 | 35504883 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs followed by SFA | NA | 0.36 | 0.456 | 33845139 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and FACs | NA | 0.36 | 0.456 | 33390847 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and FACs | NA | 0.36 | 0.456 | 34234874 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 33419140 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 33511560 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 33866606 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 34052833 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 34123797 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 34130123 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 34146553 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 34249423 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 34445421 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 34608584 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 35017469 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 35277657 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.36 | 0.456 | 35526049 |
| ACTN4 | 166 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs and RT-PCR | NA | 0.32 | 0.0074 | 29197410 |
| JAG1 | 6188 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Lapatinib | FACs followed by RT-PCR and SFA | NA | 0.32 | 0.0117 | 29895705 |
| JAG1 | 6188 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.32 | 0.0117 | 33924995 |
| NOTCH4 | 7884 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by qPCR and SFA | NA | 0.32 | 0.0042 | 31745977 |
| NOTCH4 | 7884 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Radiotherapy | Western Blotting | NA | 0.32 | 0.0042 | 30272295 |
| RTCB | 26935 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | MACs followed by SFA and RT-PCR | NA | 0.32 | 0.0021 | 29187905 |
| SOX9 | 11204 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA followed by single-cell time-of-flight mass cytometry | Up | 0.28 | 0.0244 | 34831064 |
| SNAI1 | 11128 | HTM/LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.28 | 0.0212 | 31666201 |
| ABCB1 | 40 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0604 | 31756533 |
| ABCB1 | 40 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | IF staining | NA | 0.28 | 0.0604 | 35084278 |
| ABCB1 | 40 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.28 | 0.0604 | 29036915 |
| ABCC1 | 51 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 34451892 |
| ABCC1 | 51 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.28 | 0.0212 | 29036915 |
| ALDH1A3 | 409 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Irradiation | CFA followed by Western Blotting | NA | 0.28 | 0.0201 | 34708581 |
| ALDH1A3 | 409 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR followed by SFA | NA | 0.28 | 0.0201 | 31850822 |
| ALDH1A3 | 409 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.28 | 0.0201 | 31545416 |
| ALDH1A3 | 409 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cisplatin | SFA followed by ALDEFLUOR assay | NA | 0.28 | 0.0201 | 28871147 |
| ALDH1A3 | 409 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | SFA followed by ALDEFLUOR assay | NA | 0.28 | 0.0201 | 28871147 |
| BOP1 | 15519 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.28 | 0.0021 | 33797754 |
| CCND1 | 1582 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.28 | 0.0201 | 27976692 |
| CCND1 | 1582 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.28 | 0.0201 | 29197410 |
| CCND1 | 1582 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.28 | 0.0201 | 29383157 |
| DUSP9 | 3076 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 29880481 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.28 | 0.211 | 29353288 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.28 | 0.211 | 31584203 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.28 | 0.211 | 35413424 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR followed by SFA | NA | 0.28 | 0.211 | 29907642 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.28 | 0.211 | 35055160 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 33511560 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 35017469 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.28 | 0.211 | 18366788 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.28 | 0.211 | 29552056 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.28 | 0.211 | 29552056 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.28 | 0.211 | 30584335 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs and SFA | NA | 0.28 | 0.211 | 29197410 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Docetaxel | FACs and SFA | NA | 0.28 | 0.211 | 29921732 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.28 | 0.211 | 31501409 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.28 | 0.211 | 31545416 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.28 | 0.211 | 31695775 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.28 | 0.211 | 31695775 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and Migration assay | NA | 0.28 | 0.211 | 31756533 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and SP assay | NA | 0.28 | 0.211 | 27974826 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 28951456 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 29137219 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.28 | 0.211 | 31452727 |
| ERBB2 | 3430 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by Tumorigenicity assay | NA | 0.28 | 0.0074 | 29290211 |
| ESM1 | 3466 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.28 | 0.0021 | 34502547 |
| EZH2 | 3527 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0074 | 28914785 |
| FASN | 3594 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culture of cells in electrospun scaffolds followed by Western Blotting | NA | 0.28 | 0.0074 | 34841239 |
| GLI1 | 4317 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.28 | 0.0308 | 34445421 |
| GLI2 | 4318 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.28 | 0.0106 | 34445421 |
| HES1 | 5192 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.28 | 0.0095 | 33390847 |
| HES1 | 5192 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0095 | 33924995 |
| HEY1 | 4880 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 33924995 |
| HIF1A | 4910 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.28 | 0.0106 | 34502547 |
| HIF1A | 4910 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.28 | 0.0106 | 31584203 |
| HIF1A | 4910 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cobalt Chloride | Western Blotting followed by SFA | NA | 0.28 | 0.0106 | 31584203 |
| JAK2 | 6192 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 31658701 |
| JAK2 | 6192 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.28 | 0.0053 | 31850822 |
| LDHA | 6535 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 34178639 |
| LIN28A | 15986 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0138 | 29106390 |
| LINC01133 | 49447 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting followed by SFA | NA | 0.28 | 0.0011 | 31283068 |
| LOX | 6664 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.28 | 0.0074 | 34502547 |
| MUC1 | 7508 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.28 | 0.0042 | 29353288 |
| NFKB1 | 7794 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0064 | 29073729 |
| NOTCH1 | 7881 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0477 | 33924995 |
| NOTCH1 | 7881 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.28 | 0.0477 | 30450530 |
| NOTCH2 | 7882 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting | NA | 0.28 | 0.0117 | 29100426 |
| NOTCH2 | 7882 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs and SFA | NA | 0.28 | 0.0117 | 31745977 |
| NOTCH3 | 7883 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.28 | 0.0085 | 29956731 |
| PAK1 | 8590 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 31658701 |
| PAK1 | 8590 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting and Migartion Invasion assay | NA | 0.28 | 0.0032 | 31658701 |
| PDK1 | 8809 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0053 | 29106390 |
| PDK1 | 8809 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0053 | 34052833 |
| RAD50 | 9816 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 33090711 |
| RAD50 | 9816 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Cyclophosphamide | Western Blotting | NA | 0.28 | 0.0021 | 33090711 |
| RELA | 9955 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 31497349 |
| SMO | 11119 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.28 | 0.0212 | 34445421 |
| SNAI1 | 11128 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.28 | 0.0212 | 34502547 |
| SNAI1 | 11128 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0212 | 34451892 |
| SNAI1 | 11128 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.0212 | 35017469 |
| SNAI1 | 11128 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR and SFA | NA | 0.28 | 0.0212 | 31745977 |
| SNAI1 | 11128 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.28 | 0.0212 | 29197410 |
| SNAI2 | 11094 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and Western Blotting | NA | 0.28 | 0.0159 | 33390847 |
| SNAI2 | 11094 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0159 | 34451892 |
| SNAI2 | 11094 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.28 | 0.0159 | 29197410 |
| SOX9 | 11204 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.28 | 0.0244 | 35504883 |
| STAT3 | 11364 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0223 | 34146553 |
| STAT3 | 11364 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0223 | 31619923 |
| STAT3 | 11364 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Western Blotting and SFA | NA | 0.28 | 0.0223 | 31850822 |
| TMCC3 | 29199 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 33742122 |
| VCP | 12666 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Western Blotting | NA | 0.28 | 0.0042 | 33731668 |
| YAP1 | 16262 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0117 | 34146553 |
| YAP1 | 16262 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0117 | 34445421 |
| ZEB1 | 11642 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and SP assay followed by Western Blotting and Tumorigenicity assay | NA | 0.28 | 0.0074 | 28903350 |
| MIR34A | 31635 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics and RT-PCR | Down | 0.24 | 0.0011 | 29187905 |
| STUB1 | 11427 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0011 | 29511337 |
| ALOX5 | 435 | HTM/LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0021 | 31666201 |
| BST2 | 1119 | HTM/LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0032 | 31666201 |
| CMKLR1 | 2121 | HTM/LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics and qPCR | Up | 0.24 | 0.0011 | 31666201 |
| KDM1B | 21577 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs and ALDEFLUOR assay | NA | 0.24 | 0.0021 | 29137219 |
| PPARA | 9232 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by IF staining | NA | 0.24 | 0.0021 | 33525605 |
| TERT | 11730 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by IF staining and Migration assay | NA | 0.24 | 0.0053 | 29907642 |
| THY1 | 11801 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA followed by single-cell time-of-flight mass cytometry | Up | 0.2 | 0.0371 | 34831064 |
| VIM | 12692 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA followed by single-cell time-of-flight mass cytometry | Up | 0.2 | 0.017 | 34831064 |
| ATF4 | 786 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0011 | 29601799 |
| ATF6 | 791 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0011 | 29601799 |
| AXIN2 | 904 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.2 | 0.0064 | 29383157 |
| B4GALNT1 | 4117 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.2 | 0.0042 | 33722905 |
| BCL6 | 1001 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0032 | 35357654 |
| CCL20 | 10619 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.0074 | 30052635 |
| CCR6 | 1607 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.0011 | 30052635 |
| DDIT3 | 2726 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0032 | 29601799 |
| DLGAP5 | 16864 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR and SFA | NA | 0.2 | 0.0021 | 30513573 |
| DPP4 | 3009 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | RH-1 | qRT-PCR | NA | 0.2 | 0.0085 | 31336714 |
| E2F2 | 3114 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 30021199 |
| EIF2AK3 | 3255 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0011 | 29601799 |
| ERN1 | 3449 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0021 | 29601799 |
| ETV1 | 3490 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 34052833 |
| ETV4 | 3493 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0032 | 34052833 |
| FEZF1-AS1 | 41001 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and RT-PCR followed by Migration assay | NA | 0.2 | 0.0021 | 29797562 |
| HDAC1 | 4852 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.2 | 0.0032 | 30050079 |
| HMGA2 | 5009 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.2 | 0.0042 | 35413424 |
| HMOX1 | 5013 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | CORM-A1 | SFA followed by RT-PCR | NA | 0.2 | 0.0064 | 30238818 |
| HSPA5 | 5238 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0117 | 29601799 |
| IL6 | 6018 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0191 | 34146553 |
| IL6 | 6018 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | qPCR followed by SFA | NA | 0.2 | 0.0191 | 28703802 |
| IL6 | 6018 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qPCR | NA | 0.2 | 0.0191 | 29073729 |
| IL8 | 6025 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0159 | 34146553 |
| IL8 | 6025 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Paclitaxel | qPCR followed by SFA | NA | 0.2 | 0.0159 | 28703802 |
| IL8 | 6025 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qPCR | NA | 0.2 | 0.0159 | 29073729 |
| INHBB | 6067 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.2 | 0.0064 | 35413424 |
| ITGA6 | 6142 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culture of cells in electrospun scaffolds followed by qRT-PCR | NA | 0.2 | 0.0265 | 34841239 |
| ITGA6 | 6142 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.2 | 0.0265 | 33634797 |
| ITGA6 | 6142 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.2 | 0.0265 | 29137219 |
| JUN | 6204 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.2 | 0.0053 | 35413424 |
| KIF11 | 6388 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Docetaxel | qRT-PCR followed by SFA | NA | 0.2 | 0.0011 | 29190901 |
| LINC01638 | 52425 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA and Migration Invasion assay | NA | 0.2 | 0.0011 | 30002443 |
| LncCCAT1 | NA | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR and SFA and Migration Invasion assay | NA | 0.2 | 0.0011 | 31695775 |
| LncCCAT1 | NA | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFAand Migration assay | NA | 0.2 | 0.0011 | 31695775 |
| LPAR3 | 14298 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by qPCR | NA | 0.2 | 0.0021 | 35216080 |
| LPAR6 | 15520 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by qPCR | NA | 0.2 | 0.0011 | 35216080 |
| MAPK8 | 6881 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.0032 | 30190333 |
| MET | 7029 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.2 | 0.0191 | 35413424 |
| MIR155 | 31542 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0053 | 29103027 |
| MIR181A1 | 31590 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 35029026 |
| MSI1 | 7330 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | RH-1 | qRT-PCR | NA | 0.2 | 0.0201 | 31336714 |
| MTOR1 | 3942 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR | NA | 0.2 | 0.0011 | 30050079 |
| NES | 7756 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR | NA | 0.2 | 0.0573 | 33634797 |
| NES | 7756 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.2 | 0.0573 | 35413424 |
| NES | 7756 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR followed by SFA | NA | 0.2 | 0.0573 | 29907642 |
| NOLC1 | 15608 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qRT-PCR followed by SFA | NA | 0.2 | 0.0042 | 34789263 |
| PDGFRB | 8804 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.2 | 0.0011 | 33845139 |
| PRPM1 | NA | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 35017469 |
| SLC2A1 | 11005 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0042 | 30639386 |
| SOX4 | 11200 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | Culture of cells in electrospun scaffolds followed by qRT-PCR | NA | 0.2 | 0.0042 | 34841239 |
| SRC | 11283 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0032 | 33530373 |
| TGFB2 | 11768 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR and SFA | NA | 0.2 | 0.0074 | 35413424 |
| THY1 | 11801 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | qPCR followed by SFA | NA | 0.2 | 0.0371 | 29907642 |
| THY1 | 11801 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0371 | 29103027 |
| THY1 | 11801 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by FACs | NA | 0.2 | 0.0371 | 30564555 |
| TNFSF13 | 11928 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.0021 | 30131941 |
| TNFSF13B | 11929 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.0011 | 30131941 |
| TWIST1 | 12428 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.2 | 0.0191 | 33845139 |
| TWIST1 | 12428 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Lapatinib | SFA followed by qRT-PCR | NA | 0.2 | 0.0191 | 34435487 |
| VIM | 12692 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Lapatinib | SFA followed by qRT-PCR | NA | 0.2 | 0.017 | 34435487 |
| WASF3 | 12734 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | RT-PCR | NA | 0.2 | 0.0011 | 29262622 |
| XBP1 | 12801 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0021 | 29601799 |
| CD70 | 11937 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.12 | 0.0021 | 29953653 |
| ITGB1 | 6153 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.12 | 0.018 | 31545416 |
| ITGB3 | 6156 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs and SFA | NA | 0.12 | 0.0032 | 31745977 |
| LIN28A- | 15986 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA and CFA followed by MACs | NA | 0.12 | 0.0011 | 29187905 |
| MCAM | 6934 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs | NA | 0.12 | 0.0064 | 35055160 |
| PROCR | 9452 | LTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs followed by SFA | NA | 0.12 | 0.0021 | 31545416 |
| ITGAV | 6150 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | Doxorubicin | SFA followed by single-cell time-of-flight mass cytometry | Up | 0.08 | 0.0032 | 34831064 |
| ALG5 | 20266 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| ARID1B | 18040 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| ASTE1 | 25021 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| ATP5MF | 848 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| CAMK2B | 1461 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| CCDC138 | 26531 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| CCNL1 | 20569 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| CD300LB | 30811 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| CHCHD8 | 24604 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| CHURC1 | 20099 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| CLIC5 | 13517 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| CMC1 | 28783 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| COL11A2 | 2187 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| COMMD6 | 24015 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| COPS5 | 2240 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29511337 |
| DC2 | 24448 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| DCTPP1 | 28777 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| DMACs2L | 18799 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| DNAJC19 | 30528 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| EIF3S9 | 3280 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| EPPK1 | 15577 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 19190339 |
| FAM49B | 25216 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| FBXL18 | 21874 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| GART | 4163 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 19190339 |
| GIPC3 | 18183 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| HERC1 | 4867 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| HERC4 | 24521 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29511337 |
| HUWE1 | 30892 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 29511337 |
| IMMP1L | 26317 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| ISCA1 | 28660 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| ITCH | 13890 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29511337 |
| KLK3 | 6364 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| LNX1 | 6657 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| LSM3 | 17874 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| MDM2 | 6973 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 29511337 |
| MIR103A1 | 31490 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR107 | 31496 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR1234 | 33926 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29187905 |
| MIR125B1 | 31506 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29187905 |
| MIR151A | 31762 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29187905 |
| MIR15B | 31544 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0085 | 29187905 |
| MIR16-1 | 31545 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR19B1 | 31575 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29187905 |
| MIR200C | 31580 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0074 | 29187905 |
| MIR20A | 31577 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 29187905 |
| MIR21 | 31586 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0085 | 29187905 |
| MIR224 | 31604 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 29187905 |
| MIR23B | 31606 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR24-1 | 31607 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR26B | 31612 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR27A | 31613 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 29187905 |
| MIR27B | 31614 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29187905 |
| MIR29A | 31616 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 29187905 |
| MIR29B1 | 31619 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 29187905 |
| MIR30A | 31624 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0085 | 29187905 |
| MIR365A | 33692 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR3663 | 38958 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 29187905 |
| MIR4443 | 41830 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29187905 |
| MIR4530 | 41764 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29187905 |
| MIR494 | 32084 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29187905 |
| MIR6087 | 50045 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIR6088 | 50164 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29187905 |
| MIRLET7B | 31479 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 29187905 |
| MRPL41 | 14492 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| MRPL42 | 14493 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| MRPL47 | 16652 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| MRPL54 | 16685 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| MRPS23 | 14509 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| NACA | 7629 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| NDUFA2 | 7685 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| NUP37 | 29929 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| PCNX1 | 19740 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| PDCD10 | 8761 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| PDCD5 | 8764 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| PELI1 | 8827 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 29511337 |
| PJA2 | 17481 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| PNPLA2 | 30802 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| PRPF39 | 20314 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| PRPF4B | 17346 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| PSME3 | 9570 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29511337 |
| PSORS1C2 | 17199 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| RAD51B | 9822 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| RBIS | 32235 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| RBM15 | 14959 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| RMDN1 | 24285 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| RNF7 | 10070 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| SLC38A2 | 13448 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| SNORD50A | 10200 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| SRSF7 | 10789 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| ST3GAL3 | 10866 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| TAS2R14 | 14920 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 19190339 |
| TMEM141 | 28211 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| TPRXL | 32178 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| TYW5 | 26754 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| UBE2D3 | 12476 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 29511337 |
| UBL5 | 13736 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| UGGT1 | 15663 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| USP15 | 12613 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| VHL | 12687 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| WDR53 | 28786 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| WWOX | 12799 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| WWP2 | 16804 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 29511337 |
| XIAP | 592 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 29511337 |
| ZFP41 | 26786 | HTM | Triple Negative Breast Cancer | Adenocarcinoma | MDA-MB-231 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |